Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.35 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.35 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28548174 | 0.75 | GPR3 (0.56) | GPR3LMNAHTTLCKMAP2K3 | |
| Benzonaphthyridine SCHEMBL51197 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| Benzonaphthyridine SCHEMBL29600756 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| Benzonaphthyridine SCHEMBL30897319 | 0.72 | GPR3 (1.00) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL720139 | 0.70 | GPR3 (0.54) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL4485428 | 0.67 | GPR3 (0.87) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL7052017 | 0.67 | GPR3 (0.64) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL28960747 | 0.62 | GPR3 (0.56) | GPR3LMNAHTTLCKMAP2K3 | |
| SCHEMBL2519617 | 0.62 | ALDH1A1 (0.48) | CYP1A2ALDH1A1HPGDHSD17B10TDP1 | |
| SCHEMBL10820343 | 0.62 | GPR3 (0.65) | GPR3LMNAHTTLCKMAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-113633783-A | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-105899539-B | Compounds and compositions for immunotherapy | 博笛生物科技有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-112587672-A | anti-PD-L1 conjugates for the treatment of tumors | 博笛生物科技有限公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-112546230-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112546231-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-112546238-A | anti-PD-L1 conjugates for the treatment of tumors | 博笛生物科技有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-109152832-A | Anti-CD 20 for treating tumour combines | 博笛生物科技有限公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2012168458-A1 | ZWITTERIONIC COMPOUNDS USEFUL AS CATALYSTS FOR ESTERIFICATION REACTIONS AND PROCESSES FOR THEIR PRODUCTION | ECOSYNTH BVBA (BE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20080312206-A1 | Chemical Compounds-149 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1966174-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071955-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312206-A1 | Chemical Compounds-149 | CSF3R, CSF1R, FLT3 | GPR3 1254/4885LMNA 4423/4885HTT 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.